336 related articles for article (PubMed ID: 16734512)
1. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Reni M; Mazza E; Foppoli M; Ferreri AJ
Cancer Lett; 2007 Dec; 258(2):165-70. PubMed ID: 17993246
[TBL] [Abstract][Full Text] [Related]
3. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
Shah AC; Kelly DR; Nabors LB; Oakes WJ; Hilliard LM; Reddy AT
Pediatr Blood Cancer; 2010 Dec; 55(6):1227-30. PubMed ID: 20882580
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
5. [High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Otsubo H; Takahara S; Yamaguchi Y; Saito T; Minami J; Kamiyama Y; Morikawa N; Machishima T; Osawa H; Aiba K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1277-82. PubMed ID: 20647709
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
[TBL] [Abstract][Full Text] [Related]
7. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent patients.
Cohen IJ
Pediatr Blood Cancer; 2011 Jul; 56(7):1151. PubMed ID: 21312324
[No Abstract] [Full Text] [Related]
8. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
9. [II. Primary treatment of CNS lymphoma with high-dose MTX].
Iwadate Y
Gan To Kagaku Ryoho; 2012 Jun; 39(6):892-7. PubMed ID: 22880222
[No Abstract] [Full Text] [Related]
10. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
11. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
14. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
15. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
16. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
17. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
18. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
19. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
Steinbeck JA; Stuplich M; Blasius E; Pels H; Glas M; Schlegel U; Herrlinger U
J Clin Neurosci; 2011 Nov; 18(11):1554-5. PubMed ID: 21868233
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system (CNS) lymphoma in immunocompetent patients.
Plasswilm L; Herrlinger U; Korfel A; Weller M; Küker W; Kanz L; Thiel E; Bamberg M
Ann Hematol; 2002 Aug; 81(8):415-23. PubMed ID: 12223997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
